((自动化翻译由路透提供，请见免责声明 )) (更新)
10月28日 - ** EyePoint Pharmaceuticals 盘后股价下跌8.5%至11.09美元
** EYPT 宣布 (link) 公开发行价值 1 亿美元的股票
** 摩根大通、花旗集团和古根海姆证券是此次发行的联合簿记管理人
** EYPT 股票周一收盘上涨 27.6%，报 12.12 美元
** 公司有 5350 万股流通股，市值达 6.486 亿美元--伦敦证券交易所数据
** 当天早些时候，EYPT称其 药物Duravyu在糖尿病黄斑水肿的中期试验中显示，患者远距离观察物体的能力有所改善$(DME.AU)$
** EYPT计划利用所得资金推进Duravyu的开发，并支持其早期管线开发计划。
** 糖尿病黄斑水肿是一种导致糖尿病患者视力模糊的眼部疾病。
** 亿阳信通预计 将于2025年第一季度发布全面业绩报告
** 截至上次收盘， EYPT股价累计下跌47.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.